Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (112)

III-001Nicolas Luyckx

Model-Informed Precision Dosing of Tacrolimus in Lung Transplantation Early After Surgery Using Model-Predictive Control in the tdmore Framework

Thursday 09:50-11:20

III-002Moustafa M. A. Ibrahim

The reference corrected VPC – A more intuitive model diagnostic

Thursday 09:50-11:20

III-003Panos Macheras

Understanding the gastrointestinal absorption of drugs using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models: Focus on Biowaivers

Thursday 09:50-11:20

III-004Paolo Magni

Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients

Thursday 09:50-11:20

III-005SOPHIE MAGREAULT

What clindamycin dose for which administration route in case of combination with rifampicin?

Thursday 09:50-11:20

III-006Wen Yao Mak

Population repeated time-to-event analysis of peritonitis in end-stage renal failure: Predicting the natural progression and infection risk through nationwide registry data

Thursday 09:50-11:20

III-007Victor Mangas-Sanjuan

Pharmacometric characterization of the reserpine-induced fibromyalgia model in rats to support a model-informed dosing regimen strategy for alternative disease status conditions

Thursday 09:50-11:20

III-008Jialin Mao

Human PK prediction of Kras G12C covalent inhibitors: GDC-6036, AMG-510 and MRTX-849 using PBPK approach

Thursday 09:50-11:20

III-009Mathilde Marchand

Comparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies

Thursday 09:50-11:20

III-010Hadija Marchiori

A Nonlinear Mixed Effect model of the LNA-i-miR-221 kinetics in rats for predicting key parameters of human kinetics via allometric scaling

Thursday 09:50-11:20

III-011John Maringwa

Assessing Approaches for Handling Missing Precision Measures Issue in Model-Based Meta Analysis (MBMA)

Thursday 09:50-11:20

III-012Fatima Zahra Marok

Parent-Metabolite Physiologically Based Pharmacokinetic Modeling of Mirtazapine during Drug-Drug- and Drug-Gene-Interactions

Thursday 09:50-11:20

III-013Eleonora Marostica

Population analysis of MG-ADL total score for efgartigimod Phase 3 study in myasthenia gravis patients: application of a bounded-integer model

Thursday 09:50-11:20

III-014Lara Marques

Toward Personalized Salbutamol Therapy: Validating Virtual Patient-Derived Population Pharmacokinetic Model with Real-World Data

Thursday 09:50-11:20

III-015Silvia Marquez-Megias

Development of population pharmacokinetic models using informative priors in clinical settings

Thursday 09:50-11:20

III-016Carl Julius Martensen

Data-Driven Discovery of Interpretable Feedback Mechanisms in Acute Myeloid Leukaemia using DeepPumas

Thursday 09:50-11:20

III-017Enrico Mastrostefano

Integrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment.

Thursday 09:50-11:20

III-018Andres Mazariegos Herrera

Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa

Thursday 09:50-11:20

III-019Anna Mc Laughlin

Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2

Thursday 09:50-11:20

III-020Denis Menshykau

Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases.

Thursday 09:50-11:20

III-021Matilde Merino-Sanjuán

Effects of number of time points and variability on bootstrap f2 method for the comparison of dissolution profiles

Thursday 09:50-11:20

III-022Assil MERLAUD

To quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis

Thursday 09:50-11:20

III-023Lyndsey Meyer

Advancing Quantitative Systems Pharmacology (QSP) Disease Progression Modeling with Real-World Data: Applications for Patients with Unintentional Weight Loss

Thursday 09:50-11:20

III-024Anna Mishina

A comparative benchmark study of empirical tumor size models in NSCLC clinical data

Thursday 09:50-11:20

III-025Sarang Mishra

PBPK modelling based estimation of safe, and effective Molnupiravir doses for pediatric subpopulations against SARS-CoV-2

Thursday 09:50-11:20

III-026Adrien Mitard

Modelling antibody levels impact on infection and SARS-CoV2 replication

Thursday 09:50-11:20

III-027Laurynas Mockeliunas

Model-based assessment of early bactericidal activity of rifampicin in combination with meropenem plus amoxicillin/clavulanate among adults with rifampicin-resistant pulmonary tuberculosis

Thursday 09:50-11:20

III-028Juma Ayubu MOHAMEDI

Cumulative exposure to infliximab during induction therapy predict remission in patients with Crohn’s disease and ulcerative colitis

Thursday 09:50-11:20

III-029Zeyar Mohammed Ali

Evaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies

Thursday 09:50-11:20

III-030Marcel Mohr

Integrated In Vitro/In Silico Systems Immunology Model to Quantify Drug-Induced Changes in the Immune Response after Influenza A Virus Infection – A Blueprint for the Preclinical Assessment and Clinical Translation of Infection Risks for Biologics

Thursday 09:50-11:20

III-031James Morse

Sevoflurane Pharmacokinetics and Pharmacodynamics in Adults During General Anaesthesia

Thursday 09:50-11:20

III-032Felix Müller

Understanding variability in microdialysis measurements: introducing a combined calibration approach for piperacillin and tazobactam in LPS-induced septic piglets

Thursday 09:50-11:20

III-033Veronika Musatova

Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371

Thursday 09:50-11:20

III-034Goutam Nair

Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer

Thursday 09:50-11:20

III-035Supichaya Narongchartsopon

Implications of the changes in the pharmacokinetics of raltegravir in pregnant and post-partum women undergoing antiretroviral therapy against HIV infection.

Thursday 09:50-11:20

III-036Adam Nasim

Discovering Intrinsic PK/PD Models Using Physics Informed Neural Networks

Thursday 09:50-11:20

III-037Yomna Nassar

Simulation-based evaluation of combined Likelihood Ratio Test (cLRT) and Multiple Comparison Procedure (MCP) approaches to identify a dose-response relationship in the oncology setting under different study design variables

Thursday 09:50-11:20

III-038Bach NGUYEN

Mechanistic model of antibody response, SARS-CoV-2 viral loads and genetic mutation burden to optimise molnupiravir dosing

Thursday 09:50-11:20

III-039Linh Nguyen Phuong

Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors

Thursday 09:50-11:20

III-040Chiara Nicolò

Simulating maximum tolerated dose-finding oncology trials using the InSilicoTrials cloud-based platform

Thursday 09:50-11:20

III-041Antonina Nikitich

An integrative physiologically-based model of T lymphocyte homeostasis and exogenously administered T cell kinetics

Thursday 09:50-11:20

III-043Chen Ning

Physiologically based pharmacokinetic modeling and simulation of a promising novel antiplatelet drug vicagrel and its metabolites

Thursday 09:50-11:20

III-044Jeein Noh

Machine Learning for Antibiotic-Induced Nephrotoxicity Prediction in Korean Hospitalized Patients

Thursday 09:50-11:20

III-045Pär Nordell

Predicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling

Thursday 09:50-11:20

III-046Nuo Xu

Population Pharmacokinetics and Safety Assessment of Rifapentine in Chinese Children to Inform Dosing Recommendations for Latent Tuberculosis Infection

Thursday 09:50-11:20

III-047Katharina Och

Evaluation of a pharmacokinetic model of certoparin in patients with deep vein thrombosis and severe renal insufficiency

Thursday 09:50-11:20

III-048Amaury O'Jeanson

Data-driven model selection for model-informed precision dosing: a case study with vancomycin

Thursday 09:50-11:20

III-049Ochuko Orherhe

Pharmacometric modelling to describe pharmacokinetics and exposure-response of ivermectin in adolescent patients infected with Trichuris trichiura

Thursday 09:50-11:20

III-050Marije Otto

Characterization of absorption kinetics of oral esketamine in healthy volunteers

Thursday 09:50-11:20

III-051David Outland

Towards a vertex based mechanical model of vascular endothelial cell morphology in the context of the interaction of blood flow and vascular geometry

Thursday 09:50-11:20

III-052Joanneke Overbeek

Population pharmacokinetics of cobicistat in once and twice daily regimens in various populations

Thursday 09:50-11:20

III-053Agustos Cetin Ozbey

PBPK modeling based clinical dose adaptation in liver cirrhosis patients for seven CYP and UGT enzyme substrates

Thursday 09:50-11:20

III-054Eirini Panoilia

A model based meta-analysis of the placebo response for EASI and pruritus NRS scores in moderate to severe atopic dermatitis

Thursday 09:50-11:20

III-055Orestis Papatryfonos

Modelling of tumour growth with respect to the use of anti-cancer agents

Thursday 09:50-11:20

III-056Joanna Parkinson

A streamlined, semi-automated workflow allows quick and efficient QTc and other ECG intervals modeling assessment, saving time and cost.

Thursday 09:50-11:20

III-057Zinnia Parra-Guillen

Optimal study design for pharmacokinetic modeling of teicoplanin in critically ill children, including those undergoing Continuous Renal Replacement Therapy

Thursday 09:50-11:20

III-058Madison Parrot

A Minimal PBPK Model to Predict Biodistribution of Silica Nanoparticles in Mice

Thursday 09:50-11:20

III-059Blaise Pasquiers

Translational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway

Thursday 09:50-11:20

III-060BELA PATEL

Development and benchmarking of non-generative and generative natural language processing approaches for AI-assisted pharmacometric literature curation

Thursday 09:50-11:20

III-061Anu Patel

Comparison of oxazolidinones’ exposure-response for the treatment of tuberculosis

Thursday 09:50-11:20

III-062Noel Patson

Natural disease progression model with transition probabilities to describes the continuum of Alzheimer’s disease

Thursday 09:50-11:20

III-063Sophie Peigné

Population pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate

Thursday 09:50-11:20

III-064Zorica Pejčić

Joint population pharmacokinetic model for clopidogrel and its inactive carboxylic acid metabolite

Thursday 09:50-11:20

III-065Mariana Pereira

Etravirine’s Pharmacokinetics Explored: PBPK Modeling and DDI Analysis with Efavirenz for Cancer Treatment

Thursday 09:50-11:20

III-066Carlos Perez-Ruixo

A Mechanism-Based PK/PD Model for Posdinemab (JNJ-63733657), a Humanized Monoclonal Antibody Targeting pTau, in healthy and Alzheimer’s Disease Subjects

Thursday 09:50-11:20

III-067Sara Peribanez

A physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings

Thursday 09:50-11:20

III-068Yuan Pétermann

Population pharmacokinetic model of encorafenib and binimetinb in real life settings

Thursday 09:50-11:20

III-069Kristin C. Carlsson Petri

TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology

Thursday 09:50-11:20

III-070Zvonimir Petric

Population Pharmacokinetic Model of Apovincaminic Acid (AVA) — an Exposure Proxy of Vinpocetine

Thursday 09:50-11:20

III-071Thao Pham

DeepARV-ChemBERTa: Ensemble Deep Learning to Predict Drug-Drug Interaction of Clinical Relevance with Antiretroviral Therapy

Thursday 09:50-11:20

III-072Anh Duc Pham

Population plasma and tissue pharmacokinetics of linezolid in healthy volunteers and septic patients

Thursday 09:50-11:20

III-073Morgane PHILIPP

Extension of the covariate clinical relevance determination in population pharmacokinetic analyses to the Least Absolute Shrinkage and Selection Operator (LASSO) and to Genetic Algorithm (GA) approaches

Thursday 09:50-11:20

III-074Cesar Pichardo

The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology (ISoP QSP SIG): Recent Developments and Future Vision

Thursday 09:50-11:20

III-075Antoine Pitoy

Estimation of phase III trial outcome in oncology using joint models of longitudinal biomarker and time-to-event data

Thursday 09:50-11:20

III-076Vikram Prabhakar

A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications

Thursday 09:50-11:20

III-077Laure-Hélène Préta

Antidepressants transplacental transfer modeling using ex vivo perfusion of isolated human placenta cotyledon

Thursday 09:50-11:20

III-078Alicja Puszkiel

Impact of resting energy expenditure on nivolumab pharmacokinetics and survival in metastatic non-small cell lung cancer patients

Thursday 09:50-11:20

III-079Luyuan Qi

A generic modeling framework for dose regimen optimization and patient selection in radioligand therapy

Thursday 09:50-11:20

III-081Elba Raimundez Alvarez

Evaluation of automated model development workflows for population pharmacokinetic models

Thursday 09:50-11:20

III-082Chetan Rathi

Translational PK-Tumor Growth Inhibition (TGI) modeling of type 1 PRMT and PRMT5 inhibitor combination to predict clinical response

Thursday 09:50-11:20

III-083Anne Ravix

Numerical validation of Tucuxi, a promising new Bayesian adaptation tool

Thursday 09:50-11:20

III-084Ibtissem Rebai

mlcov: New Machine Learning Based R package for Covariate Selection

Thursday 09:50-11:20

III-085Javier Reig-López

Assessment of bioequivalence outcomes of oral formulations containing racemic ibuprofen through a chiral physiologically-based pharmacokinetic model

Thursday 09:50-11:20

III-086Freek Relouw

Towards an Inflammation Simulation Model: Development and Validation of a Mathematical Model of the Human Inflammatory Response to Acute and Prolonged Lipopolysaccharide Exposure

Thursday 09:50-11:20

III-087Quentin Renou

External evaluation of a population pharmacokinetic (POP-PK) model of Cabotegravir HIV-1-infected patients treated with long-acting Cabotegravir/Rilpivirine (LA CAB-RPV)

Thursday 09:50-11:20

III-088Juan Eduardo Resendiz Galvan

What is the effective concentration of dolutegravir? A pharmacokinetic/pharmacodynamic analysis.

Thursday 09:50-11:20

III-089Silke Retlich

Leveraging Model-Based Meta-Analysis to Benchmark Chronic Kidney Disease Treatments: A Focus on Kidney Function and Proteinuria Endpoints

Thursday 09:50-11:20

III-090Mar Ribera Armengol

Causal considerations in Exposure-Response and Population PK covariate analysis

Thursday 09:50-11:20

III-091Pascale Rietveld

The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634

Thursday 09:50-11:20

III-092Camille Riff

Pharmacokinetics of inhaled AZD4604 supports lack of JAK1 systemic activity at therapeutic dose

Thursday 09:50-11:20

III-093Matthew Riggs

bbr.bayes: An Open-Source Tool to Facilitate an Efficient, Reproducible Bayesian Workflow Using NONMEM

Thursday 09:50-11:20

III-094Elena Righetti

A mechanistic model of pure and lipid-mediated alpha-synuclein aggregation to advance therapeutic strategies against Parkinson’s disease

Thursday 09:50-11:20

III-095François Riglet

Successful Establishment of Optimal Biological Dose (OBD) through PK/PD Modeling of BCL2/BIM Complex Disruption in Clinical Trials using a BCL-2 Inhibitor.

Thursday 09:50-11:20

III-096Donnia Robins

Elucidating parametric first and second-order effects in PBPK models for special scenarios using a GSA-based approach

Thursday 09:50-11:20

III-097Christelle Rodrigues

Optimizing the Dose Escalation of a new anti-CD73 monoclonal antibody for target Inhibition: A Comprehensive Preclinical and Clinical Modelling Approach

Thursday 09:50-11:20

III-098Karine Rodriguez-Fernandez

Estimation of a sensitive range of dose-adjusted FaSSIF solubility to predict the food effect on BCS II/IV drugs

Thursday 09:50-11:20

III-099Maša Roganović

External evaluation of published population pharmacokinetic models of adalimumab in inflammatory bowel disease patients

Thursday 09:50-11:20

III-100Davide Ronchi

Translational modeling of tumor response to treatment: bridging preclinical to clinical studies

Thursday 09:50-11:20

III-101Chiara Roversi

Integrated Population PK and PBPK Modelling Approaches of IAMA-6 Plasma Concentrations following Oral, Intraperitoneal and Intravenous Administrations in Three Different Preclinical Species for First in Human Dose Prediction

Thursday 09:50-11:20

III-102Karen Rowland Yeo

Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy

Thursday 09:50-11:20

III-104Mark Sale

Performance of Machine Learning Algorithms for Model Selection

Thursday 09:50-11:20

III-105Ayatallah Saleh

Evaluating the contribution of Urine Data to PopPK Models in Renal Impairment: A Case Study

Thursday 09:50-11:20

III-106Sergio Sánchez Herrero

Individualized Prediction of Gentamicin Concentration in Neonates: A Multimodal Approach of PBPK Modeling and Machine Learning

Thursday 09:50-11:20

III-107Aymara Sancho

Does shrinkage on exposure metrics truly impair E-R analysis?

Thursday 09:50-11:20

III-108Andrew Santulli

nonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation

Thursday 09:50-11:20

III-109Raphaël Saporta

Pharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC

Thursday 09:50-11:20

III-110Adriana Savoca

Integration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs

Thursday 09:50-11:20

III-111Sharon Sawe

Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy.

Thursday 09:50-11:20

III-112Franziska Schädeli Stark

Performance evaluation of the Automatic Model Development (AMD) tool with real population pharmacokinetic datasets from clinical drug development projects

Thursday 09:50-11:20

III-113Carmine Schiavone

Understanding Population Heterogeneity in Vaccine-induced Immunity: A Mechanistic Model for Immune Fingerprinting

Thursday 09:50-11:20

III-114Verena Schöning

Total and unbound flucloxacillin population pharmacokinetics in patients with Staphylococcus aureus bloodstream infection

Thursday 09:50-11:20

III-116Clarisse Schumer

Building a model from comparison of SARS-CoV-2 viral dynamics model proposed since 2020: what are the main differences?

Thursday 09:50-11:20